Terms: = Prostate cancer AND MALAT1, PRO1073, 378938, Q9UHZ2 AND Treatment
12 results:
1. Beyond the genome: malat1's role in advancing urologic cancer care.
Imran M; Abida ; Eltaib L; Siddique MI; Kamal M; Asdaq SMB; Singla N; Al-Hajeili M; Alhakami FA; AlQarni AF; Abdulkhaliq AA; Rabaan AA
Pathol Res Pract; 2024 Apr; 256():155226. PubMed ID: 38452585
[TBL] [Abstract] [Full Text] [Related]
2. [Relationship between long non-coding RNA malat1 and prostate cancer].
Zhang F; Wu CF; Luo YH; Zhou FH
Zhonghua Nan Ke Xue; 2020 Feb; 26(2):174-179. PubMed ID: 33346423
[TBL] [Abstract] [Full Text] [Related]
3. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
[TBL] [Abstract] [Full Text] [Related]
4. Signaling through estrogen receptors modulates long non-coding RNAs in prostate cancer.
Nanni S; Bacci L; Aiello A; Re A; Salis C; Grassi C; Pontecorvi A; Gaetano C; Farsetti A
Mol Cell Endocrinol; 2020 Jul; 511():110864. PubMed ID: 32413384
[TBL] [Abstract] [Full Text] [Related]
5. Total saponins from Paris forrestii (Takht) H. Li. show the anticancer and RNA expression regulating effects on prostate cancer cells.
Xia C; Chen L; Sun W; Yan R; Xia M; Wang Y; Yang D
Biomed Pharmacother; 2020 Jan; 121():109674. PubMed ID: 31810132
[TBL] [Abstract] [Full Text] [Related]
6. Whole Exome Sequencing Identifies Putative Predictors of Recurrent prostate cancer with High Accuracy.
Liu J; Mao R; Ren G; Liu X; Zhang Y; Wang J; Wang Y; Li M; Qiu Q; Wang L; Liu G; Jin S; Ma L; Ma Y; Zhao N; Yan J; Zhang H; Lin B
OMICS; 2019 Aug; 23(8):380-388. PubMed ID: 31194651
[TBL] [Abstract] [Full Text] [Related]
7. Long noncoding RNA malat1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12.
Xue D; Lu H; Xu HY; Zhou CX; He XZ
J Cell Mol Med; 2018 Jun; 22(6):3223-3237. PubMed ID: 29633510
[TBL] [Abstract] [Full Text] [Related]
8. Preclinical Study using malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract] [Full Text] [Related]
9. malat1 and HOTAIR Long Non-Coding RNAs Play Opposite Role in Estrogen-Mediated Transcriptional Regulation in prostate cancer Cells.
Aiello A; Bacci L; Re A; Ripoli C; Pierconti F; Pinto F; Masetti R; Grassi C; Gaetano C; Bassi PF; Pontecorvi A; Nanni S; Farsetti A
Sci Rep; 2016 Dec; 6():38414. PubMed ID: 27922078
[TBL] [Abstract] [Full Text] [Related]
10. The gain and loss of long noncoding RNA associated-competing endogenous RNAs in prostate cancer.
Liu D; Yu X; Wang S; Dai E; Jiang L; Wang J; Yang Q; Yang F; Zhou S; Jiang W
Oncotarget; 2016 Aug; 7(35):57228-57238. PubMed ID: 27528026
[TBL] [Abstract] [Full Text] [Related]
11. Role of Long Noncoding RNAs in Neoplasia: Special Emphasis on prostate cancer.
Alahari SV; Eastlack SC; Alahari SK
Int Rev Cell Mol Biol; 2016; 324():229-54. PubMed ID: 27017010
[TBL] [Abstract] [Full Text] [Related]
12. LncRNA malat1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.
Wang D; Ding L; Wang L; Zhao Y; Sun Z; Karnes RJ; Zhang J; Huang H
Oncotarget; 2015 Dec; 6(38):41045-55. PubMed ID: 26516927
[TBL] [Abstract] [Full Text] [Related]
